Glenmark US arm recalls 15 lakh bottles of ADHD medication in US
New Delhi: Glenmark Pharmaceuticals Inc, USA, an arm of the Mumbai-based Glenmark Pharmaceuticals, is recalling around 14.76 lakh bottles of Atomoxetine Capsules in multiple strengths in the US market.
The medication is used for the treatment of attention deficit hyperactivity disorder.
Read also: Glenmark Pharma USA launches Epinephrine Injection
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions.
Read also: Glenmark Pharmaceutical Gets CDSCO Panel Nod To Import and Market Anti-cancer Drug Tislelizumab
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.